Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma

Proteomics

Volumn 14, Issue 7-8, 2014, Pages 945-955

  Iuga, Cristina ^a,c   Seicean, Andrada ^a   Iancu, Cornel ^a   Buiga, Rareş ^b   Sappa, Praveen K ^c   Völker, Uwe ^c   Hammer, Elke ^c  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Immunohistochemistry; Pancreatic ductal adenocarcinoma; Prognostic biomarkers; Shotgun proteomics; Targeted proteomics; Technology

Indexed keywords

ADENYLYL CYCLASE ASSOCIATED PROTEIN 1; BIOLOGICAL MARKER; GALECTIN 1; LUNG RESISTANCE PROTEIN; PROLARGIN; PROTEIN; PROTEOME; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM PROTEINS; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84897384367     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300402     Document Type: Article

References (53)

1. Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics, 2010. CA. Cancer J. Clin. 2010, 60, 277-300.
2. Gräntzdörffer, I., Carl-McGrath, S., Ebert, M. P., Röcken, C., Proteomics of pancreatic cancer. Pancreas 2008, 36, 329-336.
3. Almhanna, K., Philip, P. A., Defining new paradigms for the treatment of pancreatic cancer. Curr. Treat Options Oncol. 2011, 12, 111-125.
4. McKinney, K. Q., Lee, Y. Y., Choi, H. S., Groseclose, G. et al., Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J. Proteomics 2011, 74, 79-88.
5. Chen, R., Brentnall, T. A., Pan, S., Cooke, K. et al., Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell Proteomics 2007, 6, 1331-1342.
6. Pan, S., Chen, R., Reimel, B. A., Crispin, D. A. et al., Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 2009, 30, 1132-1144.
7. Sitek, B., Sipos, B., Alkatout, I., Poschmann, G. et al., Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. J. Proteome Res. 2009, 8, 1647-1656.
8. Paulo, J. A., Lee, L. S., Banks, P. A., Steen, H., Conwell, D. L., Proteomic analysis of formalin-fixed paraffin-embedded pancreatic tissue using liquid chromatography tandem mass spectrometry. Pancreas 2012, 41, 175-185.
9. Paulo, J. A., Kadiyala, V., Brizard, S., Banks, P. A. et al., A proteomic comparison of formalin-fixed paraffin-embedded pancreatic tissue from autoimmune pancreatitis, chronic pancreatitis, and pancreatic cancer. JOP 2013, 14, 405-414.
10. Takadate, T., Onogawa, T., Fukuda, T., Motoi, F. et al., Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int. J. Cancer 2013, 132, 1368-1382.
11. Harsha, H. C., Kandasamy, K., Ranganathan, P., Rani, S. et al., A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009, 6, e1000046.
12. Winter, J. M., Yeo, C. J., Brody, J. R., Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J. Surg. Oncol. 2013, 107, 15-22
13. Thiele, T., Iuga, C., Janetzky, S., Schwertz, H. et al., Early storage lesions in apheresis platelets are induced by the activation of the integrin alphaIIbbeta(3) and focal adhesion signaling pathways. J. Proteomics 2012, 76(Spec No.), 297-315.
14. Neubert, H., Bonnert, T. P., Rumpel, K., Hunt, B. T. et al., Label-free detection of differential protein expression by LC/MALDI mass spectrometry. J. Proteome Res. 2008, 7, 2270-2279.
15. Weng, L., Dai, H., Zhan, Y., He, Y. et al., Rosetta error model for gene expression analysis. Bioinformatics 2006, 22, 1111-1121.
16. Mi, H., Muruganujan, A., Thomas, P. D., PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013, 41, D377-D386.
17. Hammer, E., Bien, S., Salazar, M. G., Steil, L. et al., Proteomic analysis of doxorubicin-induced changes in the proteome of HepG2cells combining 2D DIGE and LC-MS/MS approaches. Proteomics 2010, 10, 99-114.
18. Sherwood, C. A., Eastham, A., Lee, L. W., Risler, J. et al., Correlation between y-type ions observed in ion trap and triple quadrupole mass spectrometers. J. Proteome Res. 2009, 8, 4243-4251.
19. Zhang, H., Liu, Q., Zimmerman, L. J., Ham, A. J. et al., Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol. Cell Proteomics 2011, 10, M110 006593.
20. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
21. Chang, K. P., Wu, C. C., Chen, H. C., Chen, S. J. et al., Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 2010, 10, 2644-2660.
22. Meng, Z., Veenstra, T. D., Targeted mass spectrometry approaches for protein biomarker verification. J. Proteomics 2011, 74, 2650-2659.
23. Chen, R., Yi, E. C., Donohoe, S., Pan, S. et al., Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005, 129, 1187-1197.
24. Cheung, W., Darfler, M. M., Alvarez, H., Hood, B. L. et al., Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008, 8, 608-616.
25. Cui, Y., Wu, J., Zong, M., Song, G. et al., Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int. J. Cancer 2009, 124, 1614-1621.
26. Yamazaki, K., Takamura, M., Masugi, Y., Mori, T. et al., Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility. Lab. Invest. 2009, 89, 425-432.
27. Chen, J. H., Ni, R. Z., Xiao, M. B., Guo, J. G., Zhou, J. W., Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis. Int. 2009, 8, 193-200.
28. Chen, R., Pan, S., Ottenhof, N. A., de Wilde, R. F. et al., Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 2012, 13, 899-907.
29. Mikuriya, K., Kuramitsu, Y., Ryozawa, S., Fujimoto, M. et al., Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 2007, 30, 849-855.
30. Naidoo, K., Jones, R., Dmitrovic, B., Wijesuriya, N. et al., Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases. J. Pathol. 2012, 226, 756-763.
31. Abulaizi, M., Tomonaga, T., Satoh, M., Sogawa, K. et al., The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Int. J. Proteomics 2011, 2011, 628787.
32. Kadara, H., Behrens, C., Yuan, P., Solis, L. et al., A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin. Cancer Res. 2011, 17, 1490-1501.
33. Huang, N. F., Kurpinski, K., Fang, Q., Lee, R. J., Li, S., Proteomic identification of biomarkers of vascular injury. Am. J. Transl. Res. 2011, 3, 139-148.
34. Smeenk, H. G., Tran, T. C., Erdmann, J., van Eijck, C. H., Jeekel, J., Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch. Surg. 2005, 390, 94-103.
35. Sohn, T. A., Yeo, C. J., Cameron, J. L., Koniaris, L. et al., Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest Surg. 2000, 4, 567-579.
36. Cecconi, D., Palmieri, M., Donadelli, M., Proteomics in pancreatic cancer research. Proteomics 2011, 11, 816-828.
37. Ballehaninna, U. K., Chamberlain, R. S., Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour. Biol. 2013, 34, 3279-3292.
38. Pan, S., Brentnall, T. A., Kelly, K., Chen, R., Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Proteomics 2012, 13, 710-721.
39. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., Li, D., Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004, 64, 9018-9026.
40. Rong, Y., Wu, W., Ni, X., Kuang, T. et al., Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour. Biol. 2013, 34, 1523-1530.
41. Laurell, H., Bouisson, M., Berthelemy, P., Rochaix, P. et al., Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J. Gastroenterol 2006, 12, 3344-3351.
42. Lu, Z., Hu, L., Evers, S., Chen, J., Shen, Y., Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 2004, 4, 3975-3988.
43. Zhou, W., Capello, M., Fredolini, C., Piemonti, L. et al., Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. J. Proteome Res. 2011, 10, 1944-1952.
44. Zhou, W., Capello, M., Fredolini, C., Racanicchi, L. et al., Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J. Proteome Res. 2012, 11, 554-563.
45. Chung, J. C., Oh, M. J., Choi, S. H., Bae, C. D., Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J. Surg. 2008, 78, 245-251.
46. Stolzenberg-Solomon, R. Z., Vieth, R., Azad, A., Pietinen, P. et al., A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006, 66, 10213-10219.
47. Stolzenberg-Solomon, R. Z., Hayes, R. B., Horst, R. L., Anderson, K. E. et al., Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res. 2009, 69, 1439-1447.
48. Stolzenberg-Solomon, R. Z., Jacobs, E. J., Arslan, A. A., Qi, D. et al., Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am. J. Epidemiol. 2010, 172, 81-93.
49. Kisker, O., Onizuka, S., Becker, C. M., Fannon, M. et al., Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003, 5, 32-40.
50. Weinstein, S. J., Stolzenberg-Solomon, R. Z., Kopp, W., Rager, H. et al., Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res. 2012, 72, 1190-1198.
51. Rucci, N., Rufo, A., Alamanou, M., Capulli, M., et al., The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J. Cell Biol. 2009, 187, 669-683.
52. Holcomb, B., Yip-Schneider, M., Schmidt, C. M., The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008, 36, 225-235.
53. Lunardi, S., Muschel, R. J., Brunner, T. B., The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett. 2014, 343, 147-155.